#USA #Boston #radiopharmaceuticals #Nectin-4 #Aktis Oncology

Aktis Oncology Showcases Innovations at September Investor Conferences

Aktis Oncology, Inc., a pioneering clinical-stage oncology company, is preparing to engage with the investment community through participation in several high-profile conferences this September. With an emphasis on the future of targeted radiopharmaceuticals, Aktis aims to attract attention to their unique approach in treating patient populations that have previously been overlooked by existing treatment technologies.

Upcoming Conferences

1. Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Date: Thursday, September 11, 2025
Location: New York, N.Y.

During this summit, Aktis Oncology's President and CEO, Dr. Matthew Roden, along with other key members of the leadership team, will present insights into the innovative strategies the company is implementing. This summit serves as an exceptional opportunity for sector leaders to foster dialogue about the recent advancements in targeted therapies, and how Aktis's strategies differ from traditional methods.

2. Bank of America Healthcare Trailblazers Private Company Conference

Date: Wednesday, September 17, 2025
Location: Everett, Mass.

At this private conference, Aktis Oncology will delve deeper into their advanced therapeutic pipelines. Discussions will focus on their treatment for serious cancers through the exploitation of Nectin-4, a tumor-associated antigen often found in urothelial and other solid tumors.

Company Background

Founded with a mission to revolutionize cancer treatment, Aktis Oncology specializes in the development of targeted radiopharmaceuticals. Their most advanced program, utilizing the Nectin-4 antigen, represents a cutting-edge approach capable of reaching cancer cells more effectively than traditional therapeutic agents. The unique miniprotein radioconjugate platform developed by Aktis allows for precise targeting of tumors while minimizing the impact on healthy tissue, a critical consideration in oncology therapies.

The miniprotein technology is notable for its ability to maximize tumor penetration and promote cancer cell retention. This sophisticated technique significantly increases the therapeutic efficacy of treatment while reducing associated side effects, positioning Aktis at the forefront of the industry.

Additionally, their isotope-agnostic platform provides a remarkable advantage — it allows clinicians to engage in pre-therapeutic visualization to confirm target engagement prior to administering radiopharmaceuticals, thereby enhancing patient safety and treatment outcomes.

Moreover, Aktis Oncology has formed a strategic partnership with Eli Lilly and Company to further develop novel radioconjugates by leveraging their advanced miniprotein platform. This collaboration underscores the commitment to innovation within the field of cancer treatment.

For anyone interested in the future of oncology and targeted therapies, Aktis Oncology's presentations at the upcoming conferences are a must-watch. The potential impact of their research and development on the treatment landscape could offer new hope to patients battling difficult cancers, marking a pivotal moment in the evolution of oncology treatments.

To stay updated with their progress and learn more about their pioneering research efforts, visit Aktis Oncology's website.

For media inquiries, please contact Elizabeth Grufferman at ICR Healthcare or reach out to investor relations representative Peter Vozzo for investment details.